De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Fresh2 Group Beheer

Beheer criteriumcontroles 0/4

De CEO Fresh2 Group's is Haohan Xu, benoemd in May2023, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 24.74% van de aandelen van het bedrijf, ter waarde € 2.67M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 1.2 jaar.

Belangrijke informatie

Haohan Xu

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	24.7%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	1.2yrs

Recente managementupdates

Recent updates

CEO

Haohan Xu (28 yo)

less than a year

Tenure

Mr. Haohan Xu serves as Chief Executive Officer at Fresh2 Group Limited since May 17, 2023. He served as Co-Chief Executive Officer of Fresh2 Group Limited until May 17, 2023 and serves as its Chairman of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Haohan Xu	Chairman of the Board & CEO	less than a year	geen gegevens	24.74% CN¥ 2.7m
He Yu	Co-Founder & Chief Scientist	15.9yrs	geen gegevens	0.42% CN¥ 45.2k
Xiaoyu Li	Director & CFO	less than a year	geen gegevens	geen gegevens
Weidong Dai	China President	8.7yrs	geen gegevens	geen gegevens
Sunil Pandit	U.S. Chief Executive Officer	2.3yrs	geen gegevens	geen gegevens
Yidong Hu	Chief Strategy Officer	less than a year	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0UC0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Haohan Xu	Chairman of the Board & CEO	1.2yrs	geen gegevens	24.74% CN¥ 2.7m
Xiaoyu Li	Director & CFO	1.2yrs	geen gegevens	geen gegevens
Lee Shulman	Member of Technical Advisory Board	5.2yrs	geen gegevens	geen gegevens
Tianruo Pu	Independent Director	1.2yrs	geen gegevens	geen gegevens
Honggang Tian	Independent Director	1.2yrs	geen gegevens	geen gegevens
Zhigang Zhao	Independent Director	1.2yrs	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

42yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0UC0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw bestuur.

Fresh2 Group Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024

Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy Officer

Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive Officer

AnPac Bio-Medical Science Co., Ltd. Announces Board Resignations

Anpac Bio-Medical Science Co., Ltd. Appoints Xiaoyu Li as Chief Financial Officer

Less than half of directors are independent

Recent updates

Fresh2 Group Limited Announces Receipt of A Delinquency Compliance Alert Notice from Nasdaq

Fresh2 Group Limited announced delayed annual 10-K filing

Fresh2 Group Ltd Launches TikTok Video E-commerce Venture, Bridging the Gap Between Food Sources and Consumers

Fresh2 Group Receives Deficiency Notice from the Nasdaq Regarding Fails to Comply with the $1 Minimum Bid Price Required for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024

Ningkasai Technology (Shanghai) Co., Ltd. entered into a share purchase agreement to acquire Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. from Fresh2 Group Limited (NasdaqCM:FRES) for CNY 1.

Fresh2 Group Limited (NasdaqCM:FRES) acquired Roxe Holding Inc.

Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy Officer

Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements

Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive Officer

AnPac Bio-Medical Science Co., Ltd. (NasdaqCM:ANPC) entered into an agreement to acquire Fresh2 Ecommerce Inc for $2.1 million.

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $5 million in funding

AnPac Bio-Medical Science Announces Regaining Compliance with Nasdaq Listing Requirement

AnPac Bio-Medical Science Co., Ltd. Announces Board Resignations

AnPac Bio Granted Continued Listing by Nasdaq Hearing Panel

Anpac Bio-Medical Science Co., Ltd. Appoints Xiaoyu Li as Chief Financial Officer

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $3.67 million in funding

AnPac Bio-Medical Science Appeals Nasdaq Delisting Notice; Hearing Granted and Scheduled for October 20, 2022

AnPac Bio-Medical Science Co., Ltd. Appeals Nasdaq Delisting Notice

Less than half of directors are independent

AnPac Bio-Medical Science Co., Ltd. Announces Executive Appointments

AnPac Bio-Medical Science Co., Ltd. Approves CEO Changes

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $1.5 million in funding

Anpac Bio-Medical Science Co., Ltd. Appoints Chris Chang Yu as Co-CEO of the Company

AnPac Bio-Medical Science Co., Ltd. announced delayed 20-F filing

High number of new directors

AnPac Bio-Medical Science Co., Ltd. Announces Executive Changes

AnPac Bio-Medical Science Announces Receipt of Staff Delisting Determination from Nasdaq

AnPac Bio-Medical Science Co., Ltd. Files CDA Device for Breakthrough Medical Device Designation Request with the FDA

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in first quarter of 2022

Second quarter 2021 earnings released: CN¥2.16 loss per share (vs CN¥3.15 loss in 2Q 2020)

AnPac Bio-Medical Science Co., Ltd. Completes Major Preclinical Study, Files with National Medical Products Administration for Registration Testing of Its Multi-Cancer CDA Device

AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

First quarter 2021 earnings released: CN¥1.93 loss per share (vs CN¥2.56 loss in 1Q 2020)

AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database

Full year 2020 earnings released

NMPA Approves Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)

AnPac Bio-Medical Science Co., Ltd. Makes Significant Progress in Detecting Pre-Cancer Diseases and Recorded over 20 Types of Pre-Cancer Diseases

Anpac Bio-Medical Science Co., Ltd. Appoints Jianhua Shao as Independent Director and Member of Compensation Committee

AnPac Bio-Medical Science Co., Ltd. Completes COVID-19 Antibody Test Verification

New 90-day low: €2.76

New 90-day low: €3.66

First half earnings released

New 90-day low - €4.18

AnPac Bio-Medical Science Co., Ltd. to Report First Half, 2020 Results on Sep 10, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd